Living donor for liver transplantation

Christoph E. Broelsch, Martin Burdelski, Xavier Rogiers, Matthias Gundlach, Wolfram T. Knoefel, Thomas Langwieler, Lutz Fischer, Astrid Latta, Horst Hellwege, Franz‐Joseph Schulte, Wolff Schmiegel, Martina Sterneck, Heiner Greten, Thomas Kuechler, Gerrit Krupski, Cornelius Loeliger, Peter Kuehnl, Werner Pothmann, Jochen Schulte Am Esch – 1 July 1994 – Since living related liver transplantation was first performed in 1989, more than 150 cases have been performed worldwide, mostly in the United States and Japan.

Liver transplantation for hepatitis B virus—associated cirrhosis: A progress report

David H. Van Thiel, Harlan I. Wright, Stefano Fagiuoli – 1 July 1994 – Because of its importance as an indication for liver transplantation, the epidemiology of chronic hepatitis B disease is presented. Current knowledge relative to the pathobiological mechanisms of hepatitis B virus—related liver disease are presented, followed by a discussion of the treatment modalities currently available for use in hepatitis B virus—related liver disease.

Nodular regenerative hyperplasia of the liver graft after liver transplantation

Edward Gane, Bernard Portmann, Romil Saxena, Philip Wong, John Ramage, Roger Williams – 1 July 1994 – Nodular regenerative hyperplasia has not previously been reported in patients who have undergone orthotopic liver transplantation. In this report we describe the clinical, biochemical and histologic findings in nine liver transplant recipients in whom nodular regenerative hyperplasia developed between 6 and 144 mo (median, 64 mo) after transplantation.

Sequential treatment of biliary atresia with kasai portoenterostomy and liver transplantation: A review

Jean‐Bernard Otte, Jean De Ville De Goyet, Raymond Reding, Victoria Hausleithner, Etienne Sokal, Christophe Chardot, Benoit Debande – 1 July 1994 – Biliary atresia is the most frequent cause of chronic cholestasis in infants. When left untreated, this condition leads to death from liver insufficiency within the first 2 yr of life. The modern therapeutic approach consists of a sequential strategy with Kasai portoenterostomy as a first step and, in case of failure, liver transplantation. After portoenterostomy, no more than 20% to 30% of patients will live jaundice‐free into adulthood.

Effect of obstructive cholestasis on membrane traffic and domain‐specific expression of plasma membrane proteins in rat liver parenchmal cells

Bruno Stieger, Peter J. Meier, Lukas Landmann – 1 July 1994 – We investigated the effect of bile duct ligation and its release on membrane traffic and plasma membrane protein distribution in rat hepatocytes. Immunofluorescence studies with monoclonal antibodies against six domain‐specific surface antigens revealed that bile duct ligation leads to an accumulation of pericanalicular vesicles containing canalicular antigens.

Cancer risk in primary biliary cirrhosis: A population‐based study from Sweden

Lars Lööf, Hans‐Olov Adami, Pär Sparén, Åke Danielsson, Ljusk Siw Eriksson, Rolf Hultcrantz, Stefan Lindgren, Rolf Olsson, Hanne Prytz, Bengt‐Olof Ryden, Hanna Sandberg‐Gertzen, Sven Wallerstedt – 1 July 1994 – A cohort of 559 patients in Sweden who satisfied predetermined criteria for the diagnosis of primary biliary cirrhosis was followed with respect to the incidence of cancer during the period of 1958 to 1988. The mean follow‐up time from the time of primary biliary cirrhosis diagnosis was 9.0 ± 54 yr.

Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C

The French METAVIR Cooperative Study Group, P. Bedossa – 1 July 1994 – Liver biopsy is used as the “gold standard” for the assessment of the stage and degree of activity in chronic hepatitis C and is of major importance in evaluating the effects of treatment. Because numerous therapeutic trials are undertaken with histological control, the reproducibility of liver biopsy interpretation appears essential.

Subscribe to